Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Fra2 CRISPR/Cas9 KO Plasmid (m): sc-420403
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Fra2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Fra2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Fra2 Antibody (G-5): sc-166102
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Fra2 CRISPR/Cas9 KO Plasmid (m) | sc-420403 | 20 µg | $397.00 |
Overview
Fosl2 encodes Fra2 (FOS-like antigen 2), a basic leucine zipper transcription factor that dimerizes with JUN proteins to form AP-1 complexes controlling stimulus-dependent gene expression. In mouse cells, Fra2 integrates MAPK/ERK and JNK signaling to regulate programs linked to proliferation, differentiation, extracellular matrix remodeling, and stress responses. Fra2 activity influences lineage decisions in bone and immune compartments and modulates inflammatory transcriptional circuits. Dysregulated AP-1/Fra2 signaling has been associated with pathological remodeling and oncogenic transcriptional states, making Fosl2 a useful node for mechanistic studies of context-specific transcriptional control.
Fra2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Fosl2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Fosl2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Fosl2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Fra2 protein expression.
This CRISPR knockout system enables efficient generation of Fosl2-deficient cell models for investigation of Fra2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Fosl2 exon(s) critical for Fra2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Fosl2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Fra2 CRISPR/Cas9 KO Plasmid (m) and Fra2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Fosl2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Fra2 HDR Plasmid (m) and Fra2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Fosl2 homology arms to support homology-directed repair at defined Fosl2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.